Company Encyclopedia
View More
name
Terns Pharmaceuticals
TERN.US
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
4.361 T
TERN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst

    William Blair analyst Andy Hsieh has affirmed a Buy rating on Terns Pharmaceuticals' stock, citing the potential of TERN-701 in the chronic myeloid leukemia (CML) market. The positive outlook is supported by the success of competitor Novartis' Scemblix and promising interim data from the Phase I CARDINAL study. Truist Financial also reiterated a Buy rating with a $35.00 price target.

    Tip Ranks·
    US
    TERN
    -3.72%
    Tip Ranks·
    US
    TERN
    -3.72%

    Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

    BMO Capital Markets raised its price target for Terns Pharmaceuticals from $22.00 to $30.00, maintaining an "outperform" rating. This suggests a potential 12.40% upside from the current stock price. Other analysts have varied ratings, with an average target price of $26.63. The stock recently traded at $26.69, with a market cap of $2.40 billion.

    Market Beat·
    US
    TERN
    -3.72%
    Market Beat·
    US
    TERN
    -3.72%

    From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying?

    The biotech sector is experiencing significant growth, with stocks like Olema, Owlet, Rigel, Jazz, and Terns Pharmaceuticals reaching new highs. Key developments include Olema's public offering plans, Owlet's strong Q3 revenue, Rigel's positive trial data, Jazz's successful Phase 3 trial, and Terns' updated Phase 1 data. Investors are advised to discern between short-term price action and long-term value in this volatile market.

    rttnews·
    US
    OWLT
    -3.94%
    US
    OLMA
    +13.28%
    US
    TERN
    -3.72%
    rttnews·
    US
    OWLT
    -3.94%
    US
    OLMA
    +13.28%
    US
    TERN
    -3.72%

    Could Terns Pharmaceuticals' (TERN) Increased Conference Visibility Reflect a Shift in Management Strategy?

    Terns Pharmaceuticals reported a Q3 2025 net loss of $24.64 million and highlighted its participation in the Jefferies Global Healthcare Conference. The company aims to boost visibility for its oncology pipeline, particularly TERN-701, amid financial challenges and discontinued projects. Analysts note increased visibility but caution about ongoing financial losses and dependency on future trial results. The stock's recent price rise adds pressure on upcoming data outcomes. Despite potential overvaluation concerns, the focus remains on TERN-701's trial results and financial health.

    Simplywall·
    US
    TERN
    -3.72%
    Simplywall·
    US
    TERN
    -3.72%

    Terns Pharmaceuticals to Present at Jefferies Global Healthcare Conference

    Terns Pharmaceuticals to Present at Jefferies Global Healthcare Conference

    Reuters·
    US
    TERN
    -3.72%
    Reuters·
    US
    TERN
    -3.72%
    Posts
    View More

    As I wrote a month ago, Apple is due for a major management shake-up and the spotlight is squarely on John Ternus as Tim Cook’s successor as CEO. But I don’t get the sense anything is imminent as the ...